Steffen-Sebastian Bolz, Aphaia Pharma CSO

Apha­ia hits pri­ma­ry end­point with oral glu­cose drug in mid-stage pre­di­a­betes tri­al

The idea be­hind Apha­ia Phar­ma is to treat meta­bol­ic dis­ease ear­ly enough that pa­tients don’t progress to a type 2 di­a­betes di­ag­no­sis.

The com­pa­ny is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.